Press Announcements > FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

Press Announcements > FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease





FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

	First treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. It is also the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

Continue reading...